Drugs / 89Zr˗DFO˗REGN5054
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05259709 | Feb 2023 → Jan 2027 expected | metastatic neoplasm, neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr˗DFO˗REGN5054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05259709 ↗ |
| Modality | Diagnostic / imaging agent | “imaging agent” NCT05259709 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion during Part A and B.” NCT05259709 ↗ |